Summary Presentation of InMed Pharmaceuticals Inc.

Updated: December 16, 2025

InMed Pharmaceuticals’ Innovative Approach to Alzheimer’s and AMD Treatment

In today’s ever-evolving world of pharmaceutical innovation, InMed Pharmaceuticals emerges as a beacon of hope and groundbreaking progress. At the forefront of their research is the development of proprietary small molecule drugs that target the body’s endocannabinoid system, specifically through the CB1 and CB2 receptors. InMed is not just about maintaining the status quo; they aim to redefine treatment options with their pioneering approach to overcoming significant health challenges like Alzheimer’s disease and age-related macular degeneration (AMD).

Alzheimer’s, affecting up to 80% of dementia cases worldwide, remains one of the most formidable medical challenges of our time. Traditional treatments merely manage symptoms, failing to halt the disease’s progression. InMed’s flagship program, INM-901, offers a fresh perspective. This small, oral molecule crosses the blood-brain barrier and shows promise in reducing neuroinflammation, a critical marker in Alzheimer’s progression. The compound encourages better neuronal communication and provides neuroprotection, offering hope for millions battling the disease.

InMed doesn’t stop at Alzheimer’s. Their ocular program, targeting dry AMD with INM-089, is another triumph of their comprehensive R&D efforts. With limited existing treatments in this space, InMed’s novel therapeutic candidate aims to preserve retinal function and protect vital eye cells, setting a new benchmark in treating AMD. Complementing their pharmaceutical endeavors, their commercial segment, Baymedica, focuses on high-purity non-intoxicating cannabinoids, contributing to health and wellness sectors with substantial annual revenues.

Guided by exceptional leadership and a strategic focus on sustainable development, InMed Pharmaceuticals continues to leverage its robust financial health and strategic partnerships for future success. Their commitment to innovation and excellence makes them a compelling proposition in the pharmaceutical landscape—not just for potential partners and investors, but also for the millions who stand to benefit from their groundbreaking therapies.

Revolutionizing Alzheimer’s Treatment with INM-901

Alzheimer’s disease, which accounts for approximately 80% of dementia cases globally, presents itself as one of the most daunting medical challenges of modern times. While existing treatments primarily manage symptoms without altering disease progression, InMed’s flagship program, INM-901, introduces an innovative approach. This small, oral molecule is designed to cross the blood-brain barrier effectively a major challenge in Alzheimer’s drug development.

Research indicates that INM-901 holds promise in reducing neuroinflammation, a key driver of Alzheimer’s progression, while also enhancing neuronal communication and providing neuroprotection. These mechanisms offer a potential breakthrough in slowing the disease and improving the quality of life for millions affected. The development of INM-901 underscores InMed’s commitment to transforming Alzheimer’s treatment paradigms.

Advancing AMD Treatment with INM-089

The innovation doesn’t stop with Alzheimer’s. InMed’s ocular program targets dry age-related macular degeneration with their novel compound, INM-089. AMD is a leading cause of vision loss among the elderly, and current therapeutic options are scarce, leaving those affected with limited options.

INM-089 aims to address this gap by preserving retinal function and safeguarding crucial eye cells, offering a new benchmark in AMD treatment. This cutting-edge approach reflects InMed’s extensive R&D efforts and dedication to addressing severe medical needs. With INM-089, InMed is poised to make a significant impact in ocular health, providing hope for those beleaguered by this debilitating condition.

BayMedica’s Contribution: The Commercial Arm

Beyond their pharmaceutical advancements, InMed’s commercial arm, BayMedica, significantly enhances their market strength through the production of high-purity, non-intoxicating cannabinoids. These compounds are integral to the health and wellness sectors and contribute substantially to InMed’s annual revenues.

BayMedica exemplifies how InMed successfully integrates scientific discovery with commercial viability. By focusing on cannabinoids that meet market demands, they ensure a continuous revenue stream that supports the broader mission of InMed and solidifies their position as leaders in the cannabinoid production arena.

Strategic Growth and Leadership

Guided by exceptional leadership and a strategic focus on sustainable development, InMed Pharmaceuticals leverages its robust financial health and strategic partnerships to drive future success. Their dedication to innovation and excellence not only enhances their standing within the pharmaceutical landscape but also provides significant opportunities for potential partners and investors.

InMed’s continued commitment to developing groundbreaking therapies is not just about pursuing scientific innovation; it’s about making a tangible difference in millions of lives worldwide. As they forge ahead, InMed remains a compelling figure in the biopharmaceutical field, offering new hope for improved treatment options across some of the most challenging medical conditions today.

Overview of InMed’s Three Key Programs

InMed Pharmaceuticals is driven by an ambitious vision to deliver groundbreaking solutions in areas of unmet medical need. Their efforts are encapsulated in three pivotal programs. The first, targeting Alzheimer’s disease, utilizes the small molecule drug INM-901. The second focuses on providing a novel treatment for dry AMD with INM-089. Complementing these pharmaceutical programs is BayMedica, the company’s commercial arm dedicated to the production of high-purity cannabinoids.

Each of these programs underscores InMed’s holistic approach to medical innovation. The company’s strategic alignment of research, development, and commercialization ensures a robust pipeline poised to make meaningful impacts across multiple therapeutic areas.

INM-901 Mechanism & Preclinical Data

Alzheimer’s disease remains an insurmountable challenge for many in the medical field, affecting millions globally. InMed’s development of INM-901 introduces a new dimension to treatment paradigms by targeting the disease’s underlying mechanisms rather than simply managing symptoms.

INM-901, a small molecule drug, effectively crosses the blood-brain barrier—a significant obstacle in treating neurodegenerative diseases. Its mechanism revolves around modulating the CB1 and CB2 receptors in the brain to enhance neuronal communication and reduce neuroinflammation. Preclinical studies have demonstrated promising outcomes, suggesting its potential to slow disease progression and improve patient quality of life. This innovative approach holds promise for altering the landscape of Alzheimer’s treatment significantly.

BayMedica Commercial Strengths

While InMed’s pharmaceutical programs push the boundaries of medical research, BayMedica solidifies the company’s commercial success with its cannabinoid production capabilities. BayMedica is recognized for producing high-purity, non-intoxicating cannabinoids, supplying vital ingredients to the health and wellness sectors.

The commercial success of BayMedica not only supports InMed’s financial stability but also highlights their ability to turn scientific advancements into viable business opportunities. Their success in producing cannabinoids efficiently and at scale positions InMed as a key player in this market, enhancing the company’s reputation and influence in the biotechnology field.